Key facts
- This page summarizes Brian Piekos's Form 4 filing for Gemini Therapeutics, Inc. /DE (IRON).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2022, 19:14.
Brian Piekos - 31 May 2022 Form 4 Insider Report for Gemini Therapeutics, Inc. /DE (IRON)
- Reporting relationship
- CFO
- Issuer ticker
- IRON
- Reported as of
- 31 May 2022
- Net transaction value
- +$10,856
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2022, 19:14:01 UTC
- Prior SEC filing
- 14 Jan 2022
- Next SEC filing
- 05 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Piekos
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian Piekos filed Form 4 for Gemini Therapeutics, Inc. /DE (IRON) on 02 Jun 2022.
Change
- Previous filing in this sequence was filed on 14 Jan 2022.
- Current net transaction value: +$10,856.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IRON
transaction
Common Stock
Award
- Transaction value
- $10,856
- Shares
- +9,960
- Change %
- +130%
- Price
- $1.09*
- Shares after
- 17,615
- Date
- 31 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares were acquired under the Gemini Therapeutics, Inc. 2021 Employee Stock Purchase Plan ("ESPP").
Footnote F2
In accordance with the terms of the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022.